Swiss National Bank
SAGE

Swiss National Bank’s Sage Therapeutics SAGE Stock Holding History

Swiss National Bank’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-88,600
Closed -$481K – 2444
2024
Q4 		$481K Hold
88,600
– – ﹤0.01% 2407
2024
Q3 		$640K Hold
88,600
– – ﹤0.01% 2373
2024
Q2 		$962K Sell
88,600
-17,600
-17% -$226K ﹤0.01% 2191
2024
Q1 		$1.99M Hold
106,200
– – ﹤0.01% 1837
2023
Q4 		$2.3M Sell
106,200
-12,000
-10% -$238K ﹤0.01% 1752
2023
Q3 		$2.43M Buy
118,200
+1,200
+1% +$34.7K ﹤0.01% 1709
2023
Q2 		$5.5M Buy
117,000
+1,500
+1% +$74.6K ﹤0.01% 1255
2023
Q1 		$4.85M Sell
115,500
-13,700
-11% -$589K ﹤0.01% 1304
2022
Q4 		$4.93M Buy
129,200
+3,100
+2% +$118K ﹤0.01% 1322
2022
Q3 		$4.94M Buy
126,100
+800
+0.6% +$30.9K ﹤0.01% 1281
2022
Q2 		$4.05M Hold
125,300
– – ﹤0.01% 1449
2022
Q1 		$4.15M Buy
125,300
+9,000
+8% +$338K ﹤0.01% 1566
2021
Q4 		$4.95M Hold
116,300
– – ﹤0.01% 1471
2021
Q3 		$5.15M Buy
116,300
+500
+0.4% +$22.9K ﹤0.01% 1438
2021
Q2 		$6.58M Sell
115,800
-3,200
-3% -$226K ﹤0.01% 1292
2021
Q1 		$8.91M Buy
119,000
+1,500
+1% +$123K 0.01% 1068
2020
Q4 		$10.2M Sell
117,500
-200
-0.2% -$14.7K 0.01% 920
2020
Q3 		$7.19M Buy
117,700
+1,900
+2% +$96.3K 0.01% 973
2020
Q2 		$4.82M Buy
115,800
+15,300
+15% +$555K ﹤0.01% 1169
2020
Q1 		$2.89M Buy
100,500
+1,700
+2% +$98.4K ﹤0.01% 1225
2019
Q4 		$7.13M Buy
98,800
+2,500
+3% +$308K 0.01% 942
2019
Q3 		$13.5M Buy
96,300
+1,500
+2% +$251K 0.01% 666
2019
Q2 		$17.4M Buy
94,800
+9,400
+11% +$1.6M 0.02% 608
2019
Q1 		$13.6M Buy
85,400
+2,900
+4% +$420K 0.01% 652
2018
Q4 		$7.9M Buy
82,500
+1,400
+2% +$160K 0.01% 756
2018
Q3 		$11.5M Buy
81,100
+1,000
+1% +$154K 0.01% 686
2018
Q2 		$12.5M Buy
80,100
+700
+0.9% +$110K 0.01% 656
2018
Q1 		$12.8M Buy
79,400
+13,100
+20% +$2.22M 0.02% 641
2017
Q4 		$10.9M Buy
66,300
+13,000
+24% +$1.26M 0.01% 681
2017
Q3 		$3.32M Hold
53,300
– – ﹤0.01% 1295
2017
Q2 		$4.25M Buy
53,300
+1,200
+2% +$86.7K 0.01% 1096
2017
Q1 		$3.7M Buy
52,100
+1,600
+3% +$93.7K ﹤0.01% 1168
2016
Q4 		$2.58M Hold
50,500
– – ﹤0.01% 1387
2016
Q3 		$2.33M Buy
50,500
+9,800
+24% +$399K ﹤0.01% 1408
2016
Q2 		$1.23M Buy
40,700
+7,600
+23% +$253K ﹤0.01% 1844
2016
Q1 		$1.02M Buy
33,100
+15,600
+89% +$549K ﹤0.01% 1880
2015
Q4 		$1.02M Hold
17,500
– – ﹤0.01% 1817
2015
Q3 		$741K Buy
17,500
+2,500
+17% +$154K ﹤0.01% 1967
2015
Q2 		$1.09M Buy
15,000
+9,500
+173% +$611K ﹤0.01% 1738
2015
Q1 		$276K Hold
5,500
– – ﹤0.01% 2414
2014
Q4 		$201K Buy
+5,500
New +$205K ﹤0.01% 2503

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Swiss National Bank's SAGE Position: Q1 2025 in Review

Swiss National Bank sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 88,600 shares — an estimated $481K sold.

Swiss National Bank first reported a position in SAGE in Q4 2014 and held it in 41 quarters. The position peaked at $17.4M in Q2 2019. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Swiss National Bank reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 88,600 Sage Therapeutics shares in Q1 2025, an estimated $481K.
  • Swiss National Bank first reported a position in Sage Therapeutics in Q4 2014 and held it in 41 quarters.
  • Swiss National Bank's Sage Therapeutics position peaked at $17.4M in Q2 2019.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.